Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The aim of this phase Ib/IIa study is to investigate the maximum tolerable concentration of
abnobaVISCUM® Fraxini for intravesical instillation in patients with superficial bladder
cancer. Secondary objectives are the local and systemic tolerability, the influence on tumor
remission and the influence on the one-year recurrence rate.